B7-H3 suppresses antitumor immunity via the CCL2–CCR2–M2 macrophage axis and contributes to ovarian cancer progression

T Miyamoto, R Murakami, J Hamanishi… - Cancer Immunology …, 2022 - AACR
New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically
diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In …
被引用次数：73 相关文章

[引用][C] B7-H3 suppresses anti-tumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression

T Miyamoto - 2022 - ci.nii.ac.jp
CiNii 博士論文 - B7-H3 suppresses anti-tumor immunity via the CCL2-CCR2-M2 macrophage
axis and contributes to ovarian cancer progression CiNii 国立情報学研究所 学術情報ナビゲータ …
[HTML] nih.gov

[HTML][HTML] B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

T Miyamoto, R Murakami, J Hamanishi… - Cancer Immunology …, 2022 - ncbi.nlm.nih.gov
New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically
diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In …

B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

T Miyamoto, R Murakami… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically
diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In …
[PDF] kyoto-u.ac.jp

[PDF][PDF] B7-H3 suppresses anti-tumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression

T Miyamoto - 2022 - repository.kulib.kyoto-u.ac.jp
A role of B7-H3 in M2 macrophage-mediated immunosuppression in ovarian cancer is 22
demonstrated. The data reveal B7-H3's potential as a therapeutic target to enhance anti …

B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

T Miyamoto, R Murakami, J Hamanishi… - Cancer Immunology …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title/>< jats: p> New approaches
beyond PD-1/PD-L1 inhibition are required to target the immunologically diverse tumor …

B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.

T Miyamoto, R Murakami, J Hamanishi… - Cancer Immunology …, 2021 - europepmc.org
New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically
diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In …

B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

T Miyamoto, R Murakami… - Cancer …, 2022 - repository.kulib.kyoto-u.ac.jp
New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically
diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In …

[引用][C] B7-H3 suppresses anti-tumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression

T Miyamoto - 2022 - ci.nii.ac.jp
CiNii 博士論文 - B7-H3 suppresses anti-tumor immunity via the CCL2-CCR2-M2 macrophage
axis and contributes to ovarian cancer progression CiNii 国立情報学研究所 学術情報ナビゲータ …

B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

宮本， 泰斗， 村上， 隆介 - Cancer Immunology Research, 2022 - cir.nii.ac.jp
抄録 New approaches beyond PD-1/PD-L1 inhibition are required to target the
immunologically diverse tumor microenvironment (TME) in high-grade serous ovarian …